| Bioactivity | DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a Ki of 3 nM. DLK-IN-1 retains excellent CNS penetration and is well tolerated following multiple days of dosing at concentrations that exceed those required for DLK inhibition in the brain. DLK-IN-1 has activity in a model of Alzheimer’s Disease. | |||||||||
| Target | Ki: 3 nM (DLK). | |||||||||
| Name | DLK-IN-1 | |||||||||
| CAS | 1620574-24-4 | |||||||||
| Formula | C20H24F3N5O2 | |||||||||
| Molar Mass | 423.43 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Patel S, et al. Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease. J Med Chem. 2017 Oct 12;60(19):8083-8102. |
DLK-IN-1
CAS: 1620574-24-4 F: C20H24F3N5O2 W: 423.43
DLK-IN-1 is a selective, orally active inhibitor of dual leucine zipper kinase (DLK, MAP3K12), with a Ki of 3 nM. DLK-IN
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.